Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal
This article was originally published in PharmAsia News
Executive Summary
The U.S. subsidiary of Shionogi acquired global development and marketing rights to QuatRx Pharmaceuticals' selective estrogen receptor modulator ospemifene, building on the company's sexual medicine and women's health portfolio
You may also be interested in...
Shionogi’s Osphena May Offer Safer Alternative To Estrogen
The first oral alternative to vaginal or oral steroidal estrogens for treatment of dyspareunia due to menopause appears to have lower risks of stroke and deep vein thrombosis, according to FDA labeling.
Deals Of The Week: GSK/Abbott, AZ/Merck, Bausch & Lomb/NicOX...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com
Deals Of The Week: GSK/Abbott, AZ/Merck, Bausch & Lomb/NicOX...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com